We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...

Genmab A/S announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FR?)-targeted, TOPO1 antibody-drug ...

GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward earnings per share (EPS) is $1.4 and its forward P/E ratio is 14.5 ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...